Menu
← Oncology Approval Tracker
FDA DECISION ·
Danziten
nilotinib tartrate · Azurity Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with newly diagnosed Philadelphia chromosome-positive chronic-phase CML, or chronic- or accelerated-phase disease resistant or intolerant to prior therapy that included imatinib.
LAMPGEN ANALYSIS
Why it matters
This tablet formulation can be taken with or without food, which changes administration compared with the older nilotinib capsules.
What research teams should watch
Prescribe and verify the formulation-specific dose and continue QT and interaction checks; the products are not interchangeable milligram for milligram.
PRIMARY RECORDS